The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
The Chromosomal Basis of Cancer
Open accessAbstract
Conventional genetic theories have failed to explain why cancer (1) is not heritable and thus extremely rare in newborns, (2) is caused by non‐mutagenic carcinogens, (3) develops only years to decades after initiation by carcinogens, (4) follows pre‐neoplastic aneuploidy, (5) is aneuploid, (6) is chromosomally and phenotypically “unstable”, (7) carries specific aneusomies, (8) generates much more complex phenotypes than conventional mutation such as multidrug resistance, (9) generates nonselective phenotypes such as metastasis (no benefit at native site) and “immortality” (not necessary for tumorigenesis), and (10) does not contain carcinogenic mutations. We propose, instead, that cancer is a chromosomal disease. Accordingly carcinogenesis is initiated by random aneuploidies, which are induced by carcinogens or spontaneously. Since aneuploidy unbalances 1000s of genes, it corrupts teams of proteins that segregate, synthesize and repair chromosomes. Aneuploidy is therefore a steady source of chromosomal variations from which, in classical Darwinian terms, selection encourages the evolution and malignant progression of cancer cells. The rates of specific chromosomal variations can exceed conventional mutations by 4–11 orders of magnitude, depending on the degrees of aneuploidy. Based on their chromosomal constitution cancer cells are new cell “species” with specific aneusomies, but unstable karyotypes. The cancer‐specific aneusomies generate complex, malignant phenotypes through the abnormal dosages of 1000s of genes, just as trisomy 21 generates Down syndrome. In sum, cancer is caused by chromosomal disorganization, which increases karyotypic entropy. Thus, cancer is a chromosomal rather than a genetic disease. The chromosomal theory explains (1) non‐heritable cancer because aneuploidy is not heritable, (2) non‐mutagenic carcinogens as aneuploidogens, (3) long neoplastic latencies by the low probability of evolving new species, (4) nonselective phenotypes via genes hitchhiking with selective chromosomes, and (5) immortality because, through their cellular heterogeneity, cancers survive negative mutations and cytotoxic drugs via resistant subspecies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508 · cited 2×
“Even immortality is not a selective advantage for carcinogenesis, because many types of human cells can grow over 50 generations according to the Hayflick limit [122], and thus many more generations than are necessary to generate a lethal cancer.”
BackgroundNowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168 · cited 4×
“This inherent karyotypic–phenotypic variability of cancer cells is the reason, why most cancers are “enormously” heterogeneous populations of non-clonal and partially clonal cells, which differ from each other in “bewildering” [155] phenotypic and chromosomal variations [124,248] – even though most cancers are derived…”
BackgroundInfluentialLichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A., & Hemminki, K. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007133430201 · Cited by 4,114
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Mechanism of activation of a human oncogene
Tabin, C. J., Bradley, S. M., Bargmann, C. I., Weinberg, R. A., Papageorge, A. G., Scolnick, E. M., Dhar, R., Lowy, D. R., & Chang, E. H. (1982) · Nature · doi:10.1038/300143a0 · Cited by 1,393
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, Å., Beer, S., Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., et al. (2004) · Nature · doi:10.1038/nature03043 · Cited by 874
Principles for the Buffering of Genetic Variation
Hartman IV, J. L. (2001) · Science · doi:10.1126/science.291.5506.1001 · Cited by 808
Principles for the buffering of genetic variation
Hartman, J. L., Garvik, B., & Hartwell, L. (2001) · Science · doi:10.1126/science.1056072 · Cited by 808
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
Kallioniemi, O. P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L. C., Smith, H. S., Waldman, F. M., Pinkel, D., & Gray, J. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5321 · Cited by 555
Duesberg, P., Stindl, R., & Hehlmann, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201398998 · Cited by 106 · cited 8×
“Examples are the “high rates” (compared to mutation) at which some cancers generate metastatic cells [5,115], or generate drug-resistant variants [83, 84,113,168] (Section 2.”
BackgroundInfluentialSelf-citation
Cited by
Stepanenko, A. A., & Dmitrenko, V. V. (2015) · Gene · doi:10.1016/j.gene.2015.05.065 · Cited by 325
Isolation of Circulating Tumor Cells by Dielectrophoresis
Gascoyne, P., & Shim, S. (2014) · Cancers · doi:10.3390/cancers6010545 · Cited by 275
Mitotic catastrophe and cancer drug resistance: A link that must to be broken
Denisenko, T. V., Sorokina, I. V., Gogvadze, V., & Zhivotovsky, B. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.002 · Cited by 108
Metadata
- Authors
- Duesberg, P., Li, R., Fabarius, A., & Hehlmann, R.
- Venue
- Analytical Cellular Pathology
- Publisher
- Wiley
- Published
- 2005-01
- Volume
- 27
- Issue
- 5-6
- Pages
- 293-318
- ISSN
- 0921-8912 (ISSN-L)
- 2210-7177
- 2210-7185
- OpenAlex
- W2120655386
- Cited by
- 175
- References
- 14
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.